Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.

This study found that Janus kinase inhibitors significantly improve treatment outcomes for complex skin conditions like atopic dermatitis and alopecia areata, but their implementation requires careful safety considerations, including risk assessments for cardiovascular, malignant, and reproductive issues.

In this case series, restarting Janus kinase inhibitors after pregnancy led to hair regrowth in women with alopecia areata, but highlights the lack of standardized treatment guidelines for those planning pregnancy.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

In this review, researchers discuss 50 novel drugs approved by the FDA in 2024, highlighting key agents like vadadustat for anemia in chronic kidney disease and donanemab for Alzheimer’s, and focusing on their roles in pharmacy education and clinical decision-making.

This review suggests that oral Janus kinase inhibitors like tofacitinib, ruxolitinib, and baricitinib show promise for treating alopecia areata in adults, both in terms of efficacy and safety.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

This study found that the purified compound VB1 from Vitex negundo seeds may reduce UVA-induced skin aging by targeting MAPK1 and demonstrated its potential in mice.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.

This study found that Zizyphus jujuba fruit aqueous extract may reduce nephrotoxicity caused by ibuprofen in rats by lowering serum urea and creatinine and improving kidney antioxidant enzyme activities.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study found that Anovlar effectively reduced pain in severe dysmenorrhea cases and regulated cycles in oligomenorrhea patients, but some side effects and occasional treatment failures were reported.

This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.

Upadacitinib effectively treated severe hair loss in a child.

This case report presents an HIV-1 patient who experienced osteosclerosis and new bone formation potentially due to long-term indinavir therapy and concurrent use of vitamin A, with symptoms reducing after switching to nelfinavir.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

JAK inhibitors are generally safe for treating alopecia areata.

This review article explores the pathogenesis of vitiligo and examines various therapeutic approaches, specifically highlighting the potential use of oral and topical Janus kinase inhibitors for treatment.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

This study found that combining Juniperus communis extract with 5-Fluorouracil inhibited oral cancer cell growth more effectively than 5-FU alone, inducing cancer cell death and reducing drug resistance by affecting key cellular pathways and proteins.

This narrative review reports that Janus kinase inhibitors show promise as an effective treatment for alopecia areata, especially in patients who do not respond to conventional therapies, although further research on long-term use and topical application is needed.